262 related articles for article (PubMed ID: 20467289)
21. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
22. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
23. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
[TBL] [Abstract][Full Text] [Related]
24. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
25. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.
Patterson S; Cescon A; Samji H; Chan K; Zhang W; Raboud J; Burchell AN; Cooper C; Klein MB; Rourke SB; Loutfy MR; Machouf N; Montaner JS; Tsoukas C; Hogg RS;
BMC Infect Dis; 2015 Jul; 15():274. PubMed ID: 26183704
[TBL] [Abstract][Full Text] [Related]
26. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.
Prins M; Sabin CA; Lee CA; Devereux H; Coutinho RA
AIDS; 2000 Aug; 14(12):1829-37. PubMed ID: 10985321
[TBL] [Abstract][Full Text] [Related]
27. Predictors of Survival among Adult Ethiopian Patients in the National ART Program at Seven University Teaching Hospitals: A Prospective Cohort Study.
Fekade D; Weldegebreal T; Teklu AM; Damen M; Abdella S; Baraki N; Belayhun B; Berhan E; Kebede A; Assefa Y
Ethiop J Health Sci; 2017 Feb; 27(Suppl 1):63-71. PubMed ID: 28465654
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C and progression of HIV disease.
Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
[TBL] [Abstract][Full Text] [Related]
29. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Samji H; Cescon A; Hogg RS; Modur SP; Althoff KN; Buchacz K; Burchell AN; Cohen M; Gebo KA; Gill MJ; Justice A; Kirk G; Klein MB; Korthuis PT; Martin J; Napravnik S; Rourke SB; Sterling TR; Silverberg MJ; Deeks S; Jacobson LP; Bosch RJ; Kitahata MM; Goedert JJ; Moore R; Gange SJ;
PLoS One; 2013; 8(12):e81355. PubMed ID: 24367482
[TBL] [Abstract][Full Text] [Related]
30. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.
Zhang F; Dou Z; Ma Y; Zhang Y; Zhao Y; Zhao D; Zhou S; Bulterys M; Zhu H; Chen RY
Lancet Infect Dis; 2011 Jul; 11(7):516-24. PubMed ID: 21600849
[TBL] [Abstract][Full Text] [Related]
31. Mortality in HIV-infected women, heterosexual men, and men who have sex with men in Rio de Janeiro, Brazil: an observational cohort study.
Coelho L; Grinsztejn B; Castilho JL; De Boni R; Quintana MS; Campos DP; Ribeiro SR; Pacheco AG; Veloso VG; Luz PM
Lancet HIV; 2016 Oct; 3(10):e490-8. PubMed ID: 27658875
[TBL] [Abstract][Full Text] [Related]
32. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.
Croxford S; Kitching A; Desai S; Kall M; Edelstein M; Skingsley A; Burns F; Copas A; Brown AE; Sullivan AK; Delpech V
Lancet Public Health; 2017 Jan; 2(1):e35-e46. PubMed ID: 29249478
[TBL] [Abstract][Full Text] [Related]
33. Retention and mortality outcomes from a community-supported public-private HIV treatment programme in Myanmar.
Mburu G; Paing AZ; Myint NN; Di W; Thu KH; Ram M; Hoffmann CJ; Wang B; Naing S
J Int AIDS Soc; 2016; 19(1):20926. PubMed ID: 27784509
[TBL] [Abstract][Full Text] [Related]
34. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
Ni M; Chen X; Ma Y; Hu X
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
[TBL] [Abstract][Full Text] [Related]
35. Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey.
Holmes CB; Sikazwe I; Sikombe K; Eshun-Wilson I; Czaicki N; Beres LK; Mukamba N; Simbeza S; Bolton Moore C; Hantuba C; Mwaba P; Phiri C; Padian N; Glidden DV; Geng E
PLoS Med; 2018 Jan; 15(1):e1002489. PubMed ID: 29329301
[TBL] [Abstract][Full Text] [Related]
36. Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV.
Jansson J; Wilson DP; Carr A; Petoumenos K; Boyd MA
AIDS; 2013 May; 27(8):1245-51. PubMed ID: 23276809
[TBL] [Abstract][Full Text] [Related]
37. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.
Masiá M; Padilla S; Álvarez D; López JC; Santos I; Soriano V; Hernández-Quero J; Santos J; Tural C; del Amo J; Gutiérrez F;
AIDS; 2013 Jan; 27(2):181-9. PubMed ID: 23018442
[TBL] [Abstract][Full Text] [Related]
38. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
39. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
[TBL] [Abstract][Full Text] [Related]
40. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
Sow PS; Otieno LF; Bissagnene E; Kityo C; Bennink R; Clevenbergh P; Wit FW; Waalberg E; Rinke de Wit TF; Lange JM;
J Acquir Immune Defic Syndr; 2007 Mar; 44(3):262-7. PubMed ID: 17146376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
